AFAleksey I. Firumyants

Aleksey I. Firumyants

*This is an algorithmically generated author record based on publicly available information.

Aleksey I. Firumyants has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Cross Sectional Study of the Distribution of Macrostructural of Russian Primary School Children and Children with Disorders from the Group of Mild Cognitive Impairment and Attention Deficit Hyperactivity Disorder

    by George A. Karkashadze, Aleksey I. Firumyants, Andrey V. Fokin, Viktor V. Dyachenko, Galina N. Kireeva, Leyla S. Namazova-Baranova, Olga P. Kovtun, Elvira G. Domracheva, Nataliya S. Sergienko, Yuliya V. Nesterova, et al.

    Background . The prevalence of structural brain abnormalities among Russian children remains unknown, which hinders effective planning for the prevention of severe neurological and neurosurgical complications. The significance of a number of conditionally pathological findings that are accidentally detected by magnetic resonance imaging (MRI) in clinical practice also remains debatable. The aim of the study is to determine the frequency of macrostructural changes in the brain among primary school— age children, detected by MRI of the brain, and to assess their clinical significance in relation to disorders from the group of mild cognitive impairment (MCI) and attention deficit hyperactivity disorder (ADHD). Methods . All participants, 7–8 year old children from Chelyabinsk and Moscow, underwent an MRI scan of the brain, representatives of the Moscow cohort of children additionally underwent an in-depth clinical and psychological examination: consultation with a neurologist/psychiatrist, neuropsychological and speech therapy testing, and Wexler intelligence assessment. Results . 162 children of the combined (Chelyabinsk and Moscow) population sample and 114 Moscow children of the pathology group — ADHD, MCI and their combined variants were examined. A subgroup of 30 neurologically healthy children was also isolated from the Moscow population cohort. The most common findings in the population group were ventricular asymmetries (35.8%), dilation of perivascular spaces (11.1%), epiphysis cysts (4.3%), and an increase in the size of the large brain cistern (4.3%). According to the survey results, 2.5% of the children were referred for in-depth examination in connection with the findings. Conditionally pathological findings in general and specifically perivascular space dilation and arachnoid cysts are significantly more common among children with MCI and combined pathology of MCI + ADHD compared with neurologically healthy children and the general population of children. Conclusion . Continuous screening of Russian children using MRI can identify about 2.5% of children with suspected serious abnormalities requiring specialized monitoring. In addition, some findings that are considered insignificant may signal mild neuropathology.

  • Open Access

    Liver and spleen volumes in children with autoimmune hepatitis: association with laboratory parameters and fibrosis stage. A single-center, ambispective, cohort, non-randomized study

    by Daria V. Parakhina, Alexander S. Potapov, Matvey A. Zimin, Goar B. Movsisyan, Alexey I. Firumyants, Anatoly V. Anikin, Парахина Дарья Владимировна, Фирумянц Алексей Игоревич

    Background. Autoimmune hepatitis (AIH) in children is characterized by chronic hepatic inflammation, which may lead to organ enlargement, fibrosis progression, and development of portal hypertension. However, objective assessment of liver and spleen volume changes, and their association with laboratory parameters and fibrosis stage, remains insufficiently studied. Aim. To evaluate liver and spleen volume dynamics in children with AIH and their correlation with laboratory activity and fibrosis stage. Materials and methods. The study included 98 children with a confirmed diagnosis of AIH who were followed for 2 years. 62 of them had isolated AIH and 36 had AIH with overlapping cholangitis. All patients underwent laboratory tests (ALT, AST, GGT, albumin), MRI-based volumetric assessment of liver and spleen, and liver elastography with fibrosis staging according to the Metavir scale. Correlation, comparative and multivariate regression analyses were performed, including dynamic changes in parameters. The study was conducted with follow-up assessments at 1 year and 2 years. Results. Liver enlargement was more frequently observed in children with cholangitis (38.9%), while most patients with isolated AIH had liver volumes within the normal range or reduced. Significant correlations between liver volume, laboratory indicators, and fibrosis stage were found only in the cholangitis group. In children with isolated AIH, a positive dynamic trend was noted, including decreased ALT, AST, GGT levels and reduced liver stiffness on elastography. Spleen volume increase correlated with signs of inflammation and fibrosis but showed no statistically significant change over two years. According to regression analysis, a significant correlation was found between fibroelastography parameters and albumin levels, liver and spleen volumes, ALT and GGT levels, particularly in the group with cholangitis (R2 = 61.4%). Conclusion. Changes in liver and spleen volumes in children with autoimmune hepatitis may be associated with both disease activity and the degree of fibrosis. Patients with AIH combined with cholangitis more frequently exhibit liver enlargement, lower treatment sensitivity, and a lack of reduction in liver stiffness over time. Measuring liver and spleen volumes, along with assessing fibroelastography parameters, allows for a more comprehensive characterization of the clinical course of AIH in children.

  • Open Access

    Structural Brain Morphometry in Children with Attention Deficit Hyperactivity Disorder and Comorbid Mild Cognitive Impairments

    by George A. Karkashadze, Alexey I. Firumyants, Nikita S. Shilko, Nataliya S. Sergienko, Yulia V. Nesterova, Leonid M. Yatsyk, Elena N. Rudenko, Mikhail I. Polle, Tatiana A. Salimgareeva, Tinatin Yu. Gogberashvili, et al.

    Background. Even though mild cognitive impairments are common in patients with attention deficit hyperactivity disorder (ADHD), there are no studies of morphometric brain parameters in children with ADHD and comorbid mild cognitive impairments. Objective. The aim of the study is to determine and perform comparative analysis of MR-morphometric brain parameters in children with ADHD depending on the presence or absence of comorbid mild cognitive impairments. Methods. Participants are children aged from 7 to 8 years with ADHD without comorbid pathology (CP), ADHD with mild cognitive impairment (MCI), MCI without ADHD, and healthy children. All participants underwent brain magnetic resonance imaging followed by morphometry to obtain quantitative parameters of large brain structures, cerebral cortex gyri, basal ganglia, cerebellum, and lateral ventricles. Results. 90 children were examined. ADHD with MCI group has shown significant decrease in the volumes of caudate nuclei bilaterally and hippocampus on the right, as well as decrease in the volumes of right superior parietal gyrus, supramarginal gyrus, and frontal cortex. ADHD without CP group has shown different changes: decrease in the volume of putamen on both sides and thalamus on the left, increase in the volume of six and decrease in the volume of the cortex of four gyri, cortex thinning of four gyri with cortex thickening of one gyrus, volume increase of four cerebellar lobules. MCI without ADHD group has shown bilateral enlargement of lateral ventricles, decrease in the volume of right pallidum and seven gyri cortex, mostly on the right side, as well as decrease in the volume of four cerebellar lobules. Direct comparison between the two ADHD groups has shown significant differences up to lower total cortex volume with 5 gyri of left hemisphere and 7 gyri of right hemisphere in the ADHD with MCI group. Participants of ADHD groups compared to healthy individuals and the MCI without ADHD group did not show any age-related dynamic decrease in the volumes of cerebral cortex. Conclusion. ADHD is characterized by parallel presence of two pathogenetic processes: cerebral cortex hypoplasia and delayed age-related changes in other areas. Significant differences in morphometric parameters were revealed between ADHD without CP and ADHD with MCI. It suggests individual treatment for such patients and revision of approaches to morphometric brain studies in patients with ADHD. Enlargement of lateral ventricles in MCI may indicate the effect of perinatal pathology on these conditions’ etiology.


  • Open Access

    Brain Morphometry is an Advanced Method of Neuroimaging Mapping in Children

    by Alexey I. Firumyants, Leyla S. Namazova-Baranova, George A. Karkashadze, Olga P. Kovtun, Viktor V. Dyachenko, Nikita S. Shilko, Elena N. Rudenko, Alexey V. Meshkov, Natalia S. Sergienko, Yuliya V. Nesterova, et al.

    The use of magnetic resonance imaging in morphometry, as quantitative assessment of brain parameters (thickness, surface area, volume), allows to detect changes in many neuropsichiatric conditions that were previously considered intact. This article provides data on neuroimaging brain morphometry and effective use of this method in neurosciences.


  • Open Access

    Structural Parameters of the Brain and Bone Structures of the Head and Neck in Patients with Various Types of Mucopolysaccharidoses According to Magnetic Resonance Imaging of the Brain

    by Anastasia I. Rykunova, Nato D. Vashakmadze, Natalia V. Zhurkova, Georgiy A. Karkashadze, Ekaterina Yu. Zakharova, Alexey I. Firumyants, Andrej N. Surkov, Фирумянц Алексей Игоревич

    Background. Mucopolysaccharidoses are diseases from the group of lysosomal storage diseases that have a progressive course. CNS damage is one of the main factors in the development of severe, life-threatening complications. Aims — аssessment of structural changes in the brain and bones of the head and neck in patients with various types of mucopolysaccharidoses. Methods. The research included 136 children aged from 11 months to 17 years, 81 patients of which showed various types of mucopolysaccharidoses: MPS I — 15 people, MPS II — 37, MPS III A — 10, MPS IIIB — 4, MPS IIIC — 2, MPS IVA — 6, VI — 7 people. The control group included 56 children without neurological, psychiatric and severe somatic illnesses. Results. For mucopolysaccharidoses types I, II, III and VI, the most characteristic structural changes on the brain MRI were white matter lesions, mainly periventricular: expansion of the perivascular spaces (70%), atrophy of the cerebral hemispheres (42%), hippocampus, (31%), ventriculomegaly (6.2%), stenosis of the cervical spine (64%), hydrocephalus, expansion of the cerebrospinal fluid spaces of the posterior cranial fossa, arachnoid cysts. Conclusions. The results of the obtained data analysis made it possible to identify the macrostructural specifics of the brain disorders and cervical spine in various types of MPS, as well as their prognostic significance.


  • Open Access

    Velaglucerase alfa for treatment in children with Gaucher disease type 1: the Russian experience

    by G. B. Movsisyan, K. V. Savost`yAnov, A. A. Pushkov, N. N. Mazanova, J. V. Khazykova, А. I. Firumyants, A. S. Potapov, A. P. Fisenko, Д. В. Хазыкова

    The current gold standard for the treatment of Gaucher disease type 1 in children is enzyme replacement therapy. The efficacy and safety of treatment with velaglucerase alfa have been assessed in only a few large studies involving pediatric patients as subjects of research. In the Russian literature, there are no data available on the use of velaglucerase alfa in drug-naïve patients with Gaucher disease type 1. The aim of our study was to assess the efficacy and safety of treatment with velaglucerase alfa in children with Gaucher disease type 1. The study was approved by the Independent Ethics Committee and the Scientific Council of the National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation. All patients and/or their legal representatives gave their informed consent to the study. The efficacy of treatment with velaglucerase alfa in children with Gaucher disease type 1 was assessed by analyzing monitoring data of 15 patients aged 2 to 15 years who had been registered in the Russian Pediatric Gaucher Registry established at National Medical Research Center for Children's Health of Ministry of Healthcare of Russia over the period from 2015 to 2023. None of the patients had ever undergone enzyme replacement therapy before they were included in this study. The median age at the start of treatment was 6.5 years. We analyzed the patients' anthropometric, laboratory and instrumental data at 0, 6, 12, 24 and 36 months. The initial dose of enzyme replacement therapy ranged from 30 to 60 units/kg (with the median of 43 units/kg per infusion) once every 2 weeks based on disease severity. In as little as 6 months after the initiation of therapy with velaglucerase alfa, patients with Gaucher disease type 1 showed a statistically significant improvement in all measured parameters (p < 0.001): normalization of the median hemoglobin concentration and platelet count (from 113 to 125 g/L and from 111 to 163 × 109/L, respectively); a reduction in degree of liver and spleen enlargement (in terms of volume, from 45.1 to 17.9% and from 39.4 to 15.5%, respectively); a reduction in degree of the right liver lobe enlargement (in terms of linear measurements, from 27.2 to 11.1%); a reduction in degree of spleen enlargement (in terms of its length and width, from 73.4 to 37.8% and from 60.3 to 17.5%, respectively). Our patients had a remarkable decrease in biomarker activity after 3 years of therapy: chitotriosidase activity decreased from 2699 to 227 nmol/mL/h and glucosylsphingosine level was reduced from 204.0 to 35.3 ng/mL (р < 0.001). There were no adverse events during the course of treatment. After 6 months and 1 year of regular enzyme replacement therapy with appropriate doses of velaglucerase alfa initiated in a timely manner, children with Gaucher disease type 1 achieve normal hemoglobin concentrations and platelet counts, a reduction in biomarker activity, and a decrease in liver and spleen volumes. After 3 years of enzyme replacement therapy, patients achieve their main therapeutic goals such as the resolution of anemia and thrombocytopenia, an almost complete regression of hepatosplenomegaly and the normalization of bone mineral density and height adjusted for age.


  • Open Access

    Multifocal inflammatory levamisole-induced leukoencephalopathy in pediatric patient

    by Оксана Валерьевна Глоба, Lyudmila M. Kuzenkova, Alexey I. Firumyants, Luisa M. Abdullaeva

    Levamizole is an imidazole derivative used in the treatment of various types of cancer, dermatological diseases and parasitoses. The drug has immunomodulatory properties due to stimulating the activity of macrophages, neutrophils, monocytes and T-lymphocytes. Common side effects are gastrointestinal disorders, skin manifestations and hematological disorders. There is also a wide range of neurological side effects, such as headache, dizziness, vomiting, aphasia, blurred vision, diplopia, weakness, which can be observed in 1.3-5.0% of patients. Multifocal levamizole-induced leukoencephalopathy is one of the most striking neurological side effects of levamizole. MRI of the brain in this pathology reveals numerous foci of demyelination, located mainly periventrically, in the white matter of the cerebral hemispheres, cerebellum, brain stem, corpus callosum, basal ganglia. The treatment with corticosteroids showed the significant improvement in the condition, with almost complete regression of neurological symptoms [8]. Although the symptoms are most often manifested as subacute, over 2-8 weeks of drug use, there were reported cases with clinical manifestations developed both 1 day and months after levamizole administration. It should be noted that the neurotoxic effects of levamizole can manifest independently on the dose, even after a single application of 50 mg, which indicates that its toxic effect is a manifestation of idiosyncrasy. The literature provides a sufficient number of descriptions of clinical manifestations, MRI features and therapy of drug complications of levamizole use in adults. However, observations in pediatric practice are few. We would like to present clinical, laboratory data, imaging results, information on the treatment and follow-up of a 17-year girl who developed levamizole-induced inflammatory leukoencephalopathy and autoimmune hepatitis after self-administration of levamizole for the prevention of helminthic invasion. Leukoencephalopathy caused by levamizole should be taken into account in the differential diagnosis of demyelinating diseases, including acute multiple encephalomyelitis and multiple sclerosis, and the neurotoxic effects of the drug should also be taken into account for the timely initiation of therapy.